DexCom (NASDAQ:DXCM) Given New $99.00 Price Target at Canaccord Genuity Group

DexCom (NASDAQ:DXCM) had its price objective lifted by Canaccord Genuity Group from $89.00 to $99.00 in a report published on Monday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the medical device company’s stock.

DXCM has been the subject of several other reports. Oppenheimer lowered their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Sanford C. Bernstein increased their target price on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Stifel Nicolaus lifted their price target on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, August 23rd. Royal Bank of Canada lowered their price objective on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Finally, Wells Fargo & Company raised their target price on shares of DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $101.88.

DexCom Trading Up 0.9 %

Shares of DXCM opened at $78.41 on Monday. DexCom has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The firm has a market cap of $30.63 billion, a price-to-earnings ratio of 46.95, a PEG ratio of 2.38 and a beta of 1.12. The firm has a 50 day moving average price of $72.77 and a 200-day moving average price of $85.41. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46.

Insiders Place Their Bets

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On DexCom

Institutional investors have recently made changes to their positions in the business. Tidal Investments LLC increased its holdings in DexCom by 68.0% during the third quarter. Tidal Investments LLC now owns 36,742 shares of the medical device company’s stock valued at $2,463,000 after buying an additional 14,872 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of DexCom during the 3rd quarter valued at $381,000. World Investment Advisors LLC purchased a new stake in shares of DexCom in the 3rd quarter worth $2,351,000. Sanctuary Advisors LLC raised its holdings in DexCom by 32.2% in the 3rd quarter. Sanctuary Advisors LLC now owns 14,835 shares of the medical device company’s stock worth $1,080,000 after purchasing an additional 3,615 shares during the period. Finally, Pine Valley Investments Ltd Liability Co lifted its position in DexCom by 59.2% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 5,679 shares of the medical device company’s stock valued at $381,000 after purchasing an additional 2,111 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.